Innovex International (INVX) CEO sells 13,241 shares in planned trade

Rhea-AI Filing Summary

Innovex International, Inc. Chief Executive Officer and director Adam Anderson reported an open-market sale of company stock. On February 23, 2026, he sold 13,241 shares of common stock at $27.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025.

After this transaction, Anderson directly owned 485,581 shares of Innovex International common stock. The filing specifies that all shares in this trade were sold at the stated price per share.

Insider Trade Summary

Net Seller: 13,241 shares ($357,507)

Net Sell 1 txn

Insider Anderson Adam

Role Chief Executive Officer

Sold 13,241 shs ($358K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,241	$27.00	$358K

Holdings After Transaction: Common Stock — 485,581 shares (Direct)

Footnotes (1)

1. Sales pursuant to a Rule 10b5-1 plan adopted on March 14, 2025. All shares were sold at the price in column 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/24/2026 - 07:00 PM Learn about SEC filing dates

FAQ

What insider transaction did Innovex International (INVX) report for Adam Anderson?

Innovex International reported that CEO and director Adam Anderson sold 13,241 shares of common stock. The transaction was an open-market sale at $27.00 per share, disclosed on a Form 4 insider trading report filed for this single stock sale.

At what price did Innovex International (INVX) CEO Adam Anderson sell his shares?

Adam Anderson sold Innovex International common stock at $27.00 per share. The Form 4 notes that all 13,241 shares involved in the February 23, 2026 open-market transaction were sold at this same price, according to the pricing information disclosed in column 4.

How many Innovex International (INVX) shares does Adam Anderson hold after this sale?

After the reported sale, Adam Anderson directly holds 485,581 shares of Innovex International common stock. This post-transaction balance is disclosed in the Form 4 as the total number of shares beneficially owned following the February 23, 2026 open-market sale transaction.

Was the Innovex International (INVX) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the sale was made under a Rule 10b5-1 trading plan. That plan was adopted on March 14, 2025, indicating the trade was pre-arranged rather than initiated at the discretion of the CEO at the time of sale.

What role does Adam Anderson hold at Innovex International (INVX)?

Adam Anderson is identified as both a director and the Chief Executive Officer of Innovex International, Inc. This dual role is disclosed in the insider information section, which lists his director status and officer title alongside the reported stock sale transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderson Adam

(Last) (First) (Middle)

C/O INNOVEX INTERNATIONAL, INC.

19120 KENSWICK DRIVE

(Street)

HUMBLE TX 77338

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Innovex International, Inc. [ INVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S		13,241(1)	D	$27(2)	485,581	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sales pursuant to a Rule 10b5-1 plan adopted on March 14, 2025.

2. All shares were sold at the price in column 4.

	/s/ Matt Steinheider, Attorney-in-Fact for Adam Anderson	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.